Cantor Fitzgerald Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $33

Benzinga · 1d ago
Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $103 to $33.